SpringWorks Therapeutics announced on February 13, 2025, the wholesale acquisition cost (WAC) for its newly FDA-approved therapy, GOMEKLI (mirdametinib), at $206.25 per mg. This pricing information is a key step in the commercialization of the drug for NF1-PN.
The company estimates the average monthly cost of treatment for GOMEKLI to be approximately $22,000 for pediatric patients and $30,000 for adult patients in the U.S. This provides clarity on the expected revenue per patient for the new therapy.
The establishment of the WAC follows the recent FDA approval of GOMEKLI for adult and pediatric patients with symptomatic plexiform neurofibromas not amenable to complete resection. This pricing enables the drug's entry into the market and facilitates reimbursement discussions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.